INDEMNIFICATION AGREEMENTIndemnification Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of _________ __, 2020 by and between Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
RESEARCH AND OPTION AGREEMENTResearch and Option Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
Net Sales shall mean, with respect to any Product, the gross amount invoiced with respect thereto (whether by the Buyer, any Affiliate of the Buyer, any co-marketer, collaborator, joint venturer or other partner with the Buyer or any of its Affiliates) in the Territory, less, to the extent deducted from or on such invoice consistent with GAAP, the following items:
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. Agreement for the Rendering of Research ServicesAgreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • London
THIS AGREEMENT for the rendering of research services (the “Agreement”) is entered into as of October 11, 2020 (the “Effective Date”) by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) with offices at Hi-Tech Park, Edmond J. Safra Campus, Givat Ram, P.O.B 39135, Jerusalem 91390, Israel and Virpax Pharmaceuticals, Inc. (the “Company”) with offices at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 USA.
SECOND AMENDMENT TO THE PROMISSORY NOTE BETWEEN VIRPAX PHARMACEUTICALS, INC. AND ANTHONY P. MACKVirpax Pharmaceuticals, Inc. • November 20th, 2020 • Pharmaceutical preparations
This Second Amendment to the Promissory Note dated October 1, 2018 (the “Second Amendment”) is entered into as of October 28, 2020 (the “Effective Date”) between Virpax Pharmaceuticals, Inc., (“Virpax”) and Anthony P. Mack (“AM”). Virpax and AM may be collectively referred to herein as the “Parties.”
SECOND AMENDMENT TO THE PROMISSORY NOTE BETWEEN VIRPAX PHARMACEUTICALS, INC. AND ANTHONY P. MACKVirpax Pharmaceuticals, Inc. • November 20th, 2020 • Pharmaceutical preparations
This Second Amendment to the Promissory Note dated January 15, 2019 (“Second Amendment”) is entered into as of October 28, 2020 (the “Effective Date”) between Virpax Pharmaceuticals, Inc., (“Virpax”) and Anthony P. Mack (“AM”). Virpax and AM may be collectively referred to herein as the “Parties.”
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. AMENDMENT TO RESEARCH AND OPTION AGREEMENTResearch and Option Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Research and Option Agreement (this “Amendment”) is made effective as of May 30, 2018 (the “First Amendment Effective Date”) between Virpax Pharmaceuticals, Inc. (“Virpax”) and MedPharm Limited (“MedPharm”). Virpax and MedPharm are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.”
Agreement for the Rendering of Research ServicesAgreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • London
THIS AGREEMENT for the rendering of research services (the “Agreement”) is entered into as of May 12, 2019 (the “Effective Date”) by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) with offices at Hi-Tech Park, Edmond J. Safra Campus, Givat Ram , P.O.8 39 1 35 , Jerusalem 91390, Israel and Virpax Pharmaceuticals, In c. (the “Company”) with offices at IO I Linden wood Drive, Suite 225, Malvern, PA 19355 USA.
RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • London
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the first part; and
LICENSE AND SUBLICENSE AGREEMENTLicense and Sublicense Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England
This License AND Sub-License Agreement (“Agreement”), effective as of March 19, 2018 (the “Effective Date”), is made by and between LipocureRX, Ltd., a company organized and existing under the laws of Israel (“Lipocure”), and Virpax Pharmaceuticals, Inc., a Delaware corporation (“Virpax”).
LICENSE AGREEMENT by and between MEDPHARM LIMITED and VIRPAX PHARMACEUTICALS, LLC June 10, 2017License Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
This License Agreement (“Agreement”), effective as of June 10, 2017 (the “Effective Date”), is made by and between MedPharm Limited, a company organized and existing under the laws of the United Kingdom (“MedPharm”), and Virpax Pharmaceuticals, LLC, a limited liability company organized and existing under the laws of the State of Delaware (“Virpax”).
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. FIRST AMENDMENT TO THE RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment to the Research and License Agreement (the “First Amendment”) is made on this 3rd day of January 2020 (the “Effective Date”) by and between:
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Second Amendment to License Agreement (this “Amendment”) is made effective as of October 9, 2017 (the “Second Amendment Effective Date”) between Virpax Pharmaceuticals, Inc. (“Virpax”) and MedPharm Limited (“MedPharm”). Virpax and MedPharm are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.”
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. AMENDMENT TO LICENSE AGREEMENTLicense Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to License Agreement (this “Amendment”) is made effective as of September 2nd , 2017 (the “First Amendment Effective Date”) between Virpax Pharmaceuticals, Inc. (“Virpax”) and MedPharm Limited (“MedPharm”). Virpax and MedPharm are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.”
AMENDMENT NO. 1License Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) to the Collaboration and License Agreement dated April 11th 2019, by and between Nanomerics Ltd. (“Nanomerics”) and Virpax Pharmaceuticals, Inc. (“Virpax”) (the “Agreement”), is made effective as of Dec 30th, 2019 (the “Amendment Effective Date”).
COLLABORATION AND LICENCE AGREEMENTCollaboration and Licence Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Collaboration and Licence Agreement (this “Agreement”) is made effective as of 11th of April 2019 (the “Effective Date”), by and between
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed.Collaboration and License Agreement • November 20th, 2020 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations
This Collaboration and License Agreement (this “Agreement”) is made effective as of the 7th of August 2020 (the “Effective Date”), by and between
